Advertisement

Interleukin-6 is associated with mortality and neuropsychiatric outcomes in antiretroviral-naïve adults in Rakai, Uganda

  • Deanna SaylorEmail author
  • Anupama Kumar
  • Gertrude Nakigozi
  • Aggrey Anok
  • James Batte
  • Alice Kisakye
  • Richard Mayanja
  • Noeline Nakasujja
  • Kevin R. Robertson
  • Ronald H. Gray
  • Maria J. Wawer
  • Carlos A. Pardo
  • Ned Sacktor
Article
  • 41 Downloads

Abstract

Serum interleukin-6 (IL-6) and D-dimer have been associated with multiple adverse outcomes in HIV-infected (HIV+) individuals, but their association with neuropsychiatric outcomes, including HIV-associated neurocognitive disorder (HAND) and depression, headaches, and peripheral neuropathy have not been investigated. Three hundred ninety-nine HIV+ antiretroviral therapy (ART)-naïve adults in Rakai, Uganda, were enrolled in a longitudinal cohort study and completed a neurological evaluation, neurocognitive assessment, and venous blood draw. Half of the participants had advanced immunosuppression (CD4 count < 200 cells/μL), and half had moderate immunosuppression (CD4 count 350–500 cells/μL). All-cause mortality was determined by verbal autopsy within 2 years. HAND was determined using Frascati criteria, and depression was defined by the Center for Epidemiologic Studies-Depression (CES-D) scale. Neuropathy was defined as the presence of > 1 neuropathy symptom and > 1 neuropathy sign. Headaches were identified by self-report. Serum D-dimer levels were determined using ELISA and IL-6 levels using singleplex assays. Participants were 53% male, mean age 35 + 8 years, and mean education 5 + 3 years. Participants with advanced immunosuppression had significantly higher levels of IL-6 (p < 0.001) and a trend toward higher D-dimer levels (p = 0.06). IL-6 was higher among participants with HAND (p = 0.01), with depression (p = 0.03) and among those who died within 2 years (p = 0.001) but not those with neuropathy or headaches. D-dimer did not vary significantly by any outcome. Systemic inflammation as measured by serum IL-6 is associated with an increased risk of advanced immunosuppression, all-cause mortality, HAND, and depression but not neuropathy or headaches among ART-naïve HIV+ adults in rural Uganda.

Keywords

HIV-associated neurocognitive disorder HIV Interleukin-6 Uganda Depression All-cause mortality 

Notes

Acknowledgments

The authors would like to thank the study participants and staff at the Rakai Health Sciences Program for the time and effort they dedicated to this study.

Sources of support

This study was supported by the National Institutes of Health (MH099733, MH075673, MH080661-08, L30NS088658, NS065729-05S2, P30AI094189-01A1) with additional funding from the Johns Hopkins Center for Global Health.

Compliance with ethical standards

Written informed consent was obtained from all participants. This study was approved by the Western Institutional Review Board, the Uganda Virus Research Institute Research and Ethics Committee, and the Uganda National Council for Science and Technology.

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. Andrade BB, Hullsiek KH, Boulware DR, Rupert A, French MA, Ruxrungtham K, Montes ML, Price H, Barreiro P, Audsley J, Sher A, Lewin SR, Sereti I (2013) Biomarkers of inflammation and coagulation are associated with mortality and hepatitis flares in persons coinfected with HIV and hepatitis viruses. J Infect Dis 207(9):1379–1388CrossRefGoogle Scholar
  2. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, Gisslen M, Grant I, Heaton RK, Joseph J, Marder K, Marra CM, McArthur JC, Nunn M, Price RW, Pulliam L, Robertson KR, Sacktor N, Valcour V, Wojna VE (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69(18):1789–1799CrossRefGoogle Scholar
  3. Bjerk SM, Baker JV, Emery S, Neuhaus J, Angus B, Gordin FM, Pett SL, Stephan C, Kunisaki KM (2013) Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study. PLoS One 8(2):e56249CrossRefGoogle Scholar
  4. Bolton P, Wilk CM, Ndogoni L (2004) Assessment of depression prevalence in rural Uganda using symptom and function criteria. Soc Psychiatry Psychiatr Epidemiol 39(6):442–447CrossRefGoogle Scholar
  5. Chelune, G. J., R. K. Heaton and R. A. W. Lehman (1986). Neuropsychological and personality correlates of patients’ complaints of disability. Advances in clinical neuropsychology. R. E. Tarter and G. Goldstein. New York, Plenum Press. 3: 95–126Google Scholar
  6. Erlandson KM, Allshouse AA, Jankowski CM, Lee EJ, Rufner KM, Palmer BE, Wilson CC, MaWhinney S, Kohrt WM, Campbell TB (2013) Association of functional impairment with inflammation and immune activation in HIV type 1-infected adults receiving effective antiretroviral therapy. J Infect Dis 208(2):249–259CrossRefGoogle Scholar
  7. Fumaz CR, Gonzalez-Garcia M, Borras X, Munoz-Moreno JA, Perez-Alvarez N, Mothe B, Brander C, Ferrer MJ, Puig J, Llano A, Fernandez-Castro J, Clotet B (2012) Psychological stress is associated with high levels of IL-6 in HIV-1 infected individuals on effective combined antiretroviral treatment. Brain Behav Immun 26(4):568–572CrossRefGoogle Scholar
  8. Grund B, Baker JV, Deeks SG, Wolfson J, Wentworth D, Cozzi-Lepri A, Cohen CJ, Phillips A, Lundgren JD, Neaton JD, I. S. E. S. S. Group (2016) Relevance of interleukin-6 and D-dimer for serious non-AIDS morbidity and death among HIV-positive adults on suppressive antiretroviral therapy. PLoS One 11(5):e0155100CrossRefGoogle Scholar
  9. Kamat A, Lyons JL, Misra V, Uno H, Morgello S, Singer EJ, Gabuzda D (2012) Monocyte activation markers in cerebrospinal fluid associated with impaired neurocognitive testing in advanced HIV infection. J Acquir Immune Defic Syndr (1999) 60(3):234–243CrossRefGoogle Scholar
  10. Karnofsky, D. A. and J. H. Burchenal (1949). The clinical evaluation of chemotherapeutic agents in cancer. Evaluatoin of Chemotherapeutic Agents. C. M. Macelod. New York, Columbia University Press: 191–205Google Scholar
  11. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Neuhaus J, Nixon D, Paton NI, Neaton JD (2008) Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 5(10):e203CrossRefGoogle Scholar
  12. Lake JE, Vo QT, Jacobson LP, Sacktor N, Miller EN, Post WS, Becker JT, Palella FJ Jr, Ragin A, Martin E, Munro CA, Brown TT (2015) Adiponectin and interleukin-6, but not adipose tissue, are associated with worse neurocognitive function in HIV-infected men. Antivir Ther 20(2):235–244CrossRefGoogle Scholar
  13. Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9:179–186CrossRefGoogle Scholar
  14. Ledwaba L, Tavel JA, Khabo P, Maja P, Qin J, Sangweni P, Liu X, Follmann D, Metcalf JA, Orsega S, Baseler B, Neaton JD, Lane HC (2012) Pre-ART levels of inflammation and coagulation markers are strong predictors of death in a South African cohort with advanced HIV disease. PLoS One 7(3):e24243CrossRefGoogle Scholar
  15. Lee S, Byakwaga H, Boum Y, Burdo TH, Williams KC, Lederman MM, Huang Y, Tracy RP, Cao H, Haberer JE, Kembabazi A, Bangsberg DR, Martin JN, Hunt PW (2017) Immunologic pathways that predict mortality in HIV-infected Ugandans initiating ART. J Infect Dis 215:1270–1274CrossRefGoogle Scholar
  16. Margolick, J. B., O. Martinez-Maza, L. P. Jacobson, J. Lopez, X. Li and J. P. Phair (2013). Frailty and circulating markers of inflammation in HIV-infected and -uninfected men in the Multicenter AIDS Cohort Study (MACS). 20th Conference on Retroviruses and Opportunistic Infection. Atlanta, GAGoogle Scholar
  17. Masia, M., S. Padilla, M. Fernandez, X. Barber, S. Moreno, J. A. Iribarren, J. Portilla, A. Pena, F. Vidal, F. Gutierrez and CoRis (2017). “Contribution of oxidative stress to non-AIDS events in HIV-infected patients.” J Acquir Immune Defic Syndr 75(2): e36-e44Google Scholar
  18. McDonald B, Moyo S, Gabaitiri L, Gaseitsiwe S, Bussmann H, Koethe JR, Musonda R, Makhema J, Novitsky V, Marlink RG, Wester CW, Essex M (2013) Persistently elevated serum interleukin-6 predicts mortality among adults receiving combination antiretroviral therapy in Botswana: results from a clinical trial. AIDS Res Hum Retrovir 29(7):993–999CrossRefGoogle Scholar
  19. Montoya JL, Iudicello J, Oppenheim HA, Fazeli PL, Potter M, Ma Q, Mills PJ, Ellis RJ, Grant I, Letendre SL, Moore DJ, H. I. V. N. R. P. Group (2017) Coagulation imbalance and neurocognitive functioning in older HIV-positive adults on suppressive antiretroviral therapy. AIDS 31(6):787–795CrossRefGoogle Scholar
  20. Nitkiewicz J, Borjabad A, Morgello S, Murray J, Chao W, Emdad L, Fisher PB, Potash MJ, Volsky DJ (2017) HIV induces expression of complement component C3 in astrocytes by NF-kappaB-dependent activation of interleukin-6 synthesis. J Neuroinflammation 14(1):23CrossRefGoogle Scholar
  21. Norcini Pala A, Steca P, Bagrodia R, Helpman L, Colangeli V, Viale P, Wainberg ML (2016) Subtypes of depressive symptoms and inflammatory biomarkers: an exploratory study on a sample of HIV-positive patients. Brain Behav Immun 56:105–113CrossRefGoogle Scholar
  22. Piggott DA, Varadhan R, Mehta SH, Brown TT, Li H, Walston JD, Leng SX, Kirk GD (2015) Frailty, inflammation, and mortality among persons aging with HIV infection and injection drug use. J Gerontol A Biol Sci Med Sci 70(12):1542–1547CrossRefGoogle Scholar
  23. Saylor D, Dickens AM, Sacktor N, Haughey N, Slusher B, Pletnikov M, Mankowski JL, Brown A, Volsky DJ, McArthur JC (2016) HIV-associated neurocognitive disorder--pathogenesis and prospects for treatment. Nat Rev Neurol 12(4):234–248CrossRefGoogle Scholar
  24. Sinha A, Ma Y, Scherzer R, Hur S, Li D, Ganz P, Deeks SG, Hsue PY (2016) Role of T-cell dysfunction, inflammation, and coagulation in microvascular disease in HIV. J Am Heart Assoc 5(12)Google Scholar
  25. So-Armah KA, Tate JP, Chang CH, Butt AA, Gerschenson M, Gibert CL, Leaf D, Rimland D, Rodriguez-Barradas MC, Budoff MJ, Samet JH, Kuller LH, Deeks SG, Crothers K, Tracy RP, Crane HM, Sajadi MM, Tindle HA, Justice AC, Freiberg MS, Team VP (2016) Do biomarkers of inflammation, monocyte activation, and altered coagulation explain excess mortality between HIV infected and uninfected people? J Acquir Immune Defic Syndr 72(2):206–213CrossRefGoogle Scholar
  26. Van der Watt JJ, Wilkinson KA, Wilkinson RJ, Heckmann JM (2014) Plasma cytokine profiles in HIV-1 infected patients developing neuropathic symptoms shortly after commencing antiretroviral therapy: a case-control study. BMC Infect Dis 14:71CrossRefGoogle Scholar
  27. Warriner EM, Rourke SB, Rourke BP, Rubenstein S, Millikin C, Buchanan L, Connelly P, Hyrcza M, Ostrowski M, Der S, Gough K (2010) Immune activation and neuropsychiatric symptoms in HIV infection. J Neuropsychiatr Clin Neurosci 22(3):321–328CrossRefGoogle Scholar
  28. Weissman MM, Sholomskas D, Pottenger M, Prusoff BA, Locke BZ (1977) Assessing depressive symptoms in five psychiatric populations: a validation study. Am J Epidemiol 106(3):203–214CrossRefGoogle Scholar

Copyright information

© Journal of NeuroVirology, Inc. 2019

Authors and Affiliations

  • Deanna Saylor
    • 1
    • 2
    Email author
  • Anupama Kumar
    • 1
  • Gertrude Nakigozi
    • 3
  • Aggrey Anok
    • 3
  • James Batte
    • 3
  • Alice Kisakye
    • 3
  • Richard Mayanja
    • 3
  • Noeline Nakasujja
    • 4
  • Kevin R. Robertson
    • 5
  • Ronald H. Gray
    • 6
  • Maria J. Wawer
    • 6
  • Carlos A. Pardo
    • 1
  • Ned Sacktor
    • 1
  1. 1.Department of NeurologyJohns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Department of Internal MedicineUniversity of Zambia School of MedicineLusakaZambia
  3. 3.Rakai Health Sciences ProgramKalisizoUganda
  4. 4.Department of PsychiatryMakerere UniversityKampalaUganda
  5. 5.Department of NeurologyUniversity of North Carolina – Chapel HillChapel HillUSA
  6. 6.Department of EpidemiologyJohns Hopkins University Bloomberg School of Public HealthBaltimoreUSA

Personalised recommendations